[Antiretroviral prophylaxis after non-occupational exposure to HIV in Abidjan (Cote d'Ivoire)].
OBJECTIVE
The aim of this study was to assess the tolerability and adherence to all non-occupational post-exposure prophylaxis (PEP) for cases of HIV exposure in Abidjan.


METHODS
We retrospectively studied all post-exposure prophylaxis for non-occupational exposures to HIV prescribed from January 1st, 2000 to December 31st, 2007 in the Abidjan infectious diseases department. We analyzed the types of exposure, socio-demographic characteristics of patients, antiretroviral therapy regimens, adherence and tolerability, duration of the treatment, and post-exposure follow-up.


RESULTS
Over these eight years, we managed 128 consultations for non-professional exposures to HIV (50 male [39%], 78 female patients [61%]), average age 24.8 years (four-54 years). The most frequent exposures were due to rape (n=74), condom rupture (n=29), and occasional unprotected sex (n=21). The average delay before consultation was 20.8 hours. The antiretroviral chemoprophylaxis included a protease inhibitor in 93% of the cases; 80.5% of patients completed 28 days of chemoprophylaxis, while 8.6% interrupted the treatment, and 10.9% were lost to follow-up. The most frequent adverse effects were gastrointestinal, reported by 79 patients (61.7%). Only 34 patients (26.6%) returned for clinical and biological post-exposure follow-up with HIV control at third month, without documented seroconversion.


CONCLUSIONS
Cases of sexual exposure to HIV are the main indication for post-exposure prophylaxis in Abidjan, except for occupational exposure to blood. However, post-exposure prophylaxis should be available in the units of primary care, such as emergencies departments.
Ehui
E
E
Service des maladies infectieuses et tropicales, CHU de Treichville, 01 BP V 3, Abidjan 01, Cote-d'Ivoire. docehui@yahoo.fr
Tanon
A
A
Guié
P
P
Aba
T
T
Toa-Lou
C
C
Kassi
A
A
Ouattara
I
I
Kouakou
G
G
Mossou
C
C
Kakou
A
A
Eholié
S
S
Aoussi
E
E
Bissagnéné
E
E
D000293:Adolescent; D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001734:Bites, Human; D002648:Child; D002675:Child, Preschool; D017280:Condoms; D007560:Cote d'Ivoire; D004868:Equipment Failure; D005260:Female; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D015658:HIV Infections / Q000517:prevention & control* / Q000635:transmission; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D006679:HIV Seropositivity; D006801:Humans; D008297:Male; D008875:Middle Aged; D016602:Needlestick Injuries; D010349:Patient Compliance; D056990:Post-Exposure Prophylaxis / Q000706:statistics & numerical data; D011902:Rape; D012189:Retrospective Studies; D016896:Treatment Outcome; D047568:Unsafe Sex; D055815:Young Adult
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors